Gender Dysphoric / Gender Incongruent. Hormone therapy in adults
PDF (Español (España))
HTML (Español (España))


cross-sex hormones
Gender Dysphoric
Gender Incongruent

How to Cite

Sierra Osorio, A. M., Rivera, M. A., & Tovar, H. (2018). Gender Dysphoric / Gender Incongruent. Hormone therapy in adults. Revista Colombiana De Endocrinología, Diabetes &Amp; Metabolismo, 5(4), 32–36.


Hormone affirmation therapy for transgender adults aims to allow the concordance between the biological sex and the gender identity of the patient, mitigating the discomfort related to the incongruence they experience. Current treatment recommendations are based primarily on the clinical experience of experts in the field and in extrapolations of the management of people with hypogonadism. Prior to the start of hormone therapy, is essential that a expert psychiatrist in dysphoria confirm the diagnosis and that the patient is willing to receive psychotherapeutic support throughout the affirmation process, have a real life experience adopting a full role of the opposite gender for 12 months and know the consequences, risks and benefits of the therapy. It is required to maintain the serum concentration of crossed sex hormones within the physiological range to prevent long-term adverse results.
PDF (Español (España))
HTML (Español (España))


1. Ahmad S, Barrett J, Beaini AY, Bouman WP, Davies A, Greener HM, et al. Gender dysphoria services: a guide for general practitioners and other healthcare staff. Sexual and Relationship Therapy. 2013; 28(3):172-85
2. American Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders (5th ed.). Washington, DC.
3. Moratalla NL, Canelas AC. Transexualidad: una alteración cerebral que comienza a conocerse. Cuadernos de bioética. 2016; 27(1ª):1ª
4. Cécile A. Unger. Hormone therapy for transgender patients. Transl Androl Urol. 2016; 5(6):877-884
5. Arcelus J, Bouman WP, Van Den Noortgate W, Claes L, Witcomb G, Fernandez-Aranda F. Systematic review and meta-analysis of prevalence studies in transsexualism. Eur Psychiatry. 2015; 30(6):807-15.
6. Gómez Gil, Trilla García. Estimación de la prevalencia, incidencia y razón de sexos del transexualismo en Cataluña según la demanda asistencial. Actas Esp Psiquiatr 2006; 34(0):00-00
7. De Bogotá AM. Balances y Perspectivas: Política Pública para la Garantía Plena de los Derechos de las Personas Lesbianas, Gays, Bisexuales y Transgeneristas-LGBT-y sobre Identidades de Género y Orientaciones Sexuales en el Distrito Capital. Bogotá [Links]. 2011.
8. Balances y perspectivas de la política pública LGBTI 2012 – 2015. Secretaría Distrital de Planeación. Bogotá
9. Wylie C. Hembree, Peggy T. Cohen-Kettenis, Louis Gooren, Sabine E. et al. Endocrine Treatment of Gender-Dysphoric/ Gender-Incongruent Persons: An Endocrine Society* Clinical Practice Guideline. J Clin Endocrinol Metab, November 2017, 102(11):3869–3903
10. Wylie K, Barrett J, Besser M, Bouman WP, Bridgman M, Clayton A, et al. Good prac tice guidelines for the assessment and treatment of adults with gender dysphoria. Sexual and Relationship Therapy. 2014; 29(2):154-214.
11. Hembree WC, Cohen-Kettenis P, Delemarre-van de Waal HA, Gooren LJ, Meyer WJ, Spack NP, et al. Endocrine treatment of transsexual persons: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2009; 94(9):3132-54
12. Tangpricha V, den Heijer M. Oestrogen and anti-androgen therapy for transgender women. Lancet Diabetes Endocrinol. 2017; 5(4):291-300.
13. Maraka S, Singh Ospina N, Rodriguez-Gutierrez. Sex Steroids and Cardiovascular Outcomes in Transgender Individuals: A Systematic Review and Meta-Analysis. J Clin Endocrinol Metab. 2017 Nov 1; 102(11):3914-3923.
14. Shatzel JJ, Connelly KJ, DeLoughery TG. Thrombotic issues in transgender medicine: A review. Am J Hematol. 2017 Feb; 92(2):204-208.
15. Singh-Ospina N, Maraka S, Rodriguez-Gutierrez R, Davidge-Pitts C. Effect of Sex Steroids on the Bone Health of Transgender Individuals: A Systematic Review and Meta-Analysis. J Clin Endocrinol Metab. 2017 Nov 1; 102(11):3904-3913.
16. Irwig MS. Testosterone therapy for transgender men. Lancet Diabetes Endocrinol. 2017; 5(4):301-11
17. Gooren LJ, Sungkaew T, Giltay EJ, Guadamuz TE. Cross-sex hormone use, functional health and mental well-being among transgender men (Toms) and transgender women (Kathoeys) in Thailand. Cult Health Sex 2015; 17: 92–103.
18. Mueller A, Haeberle L, Zollver H, et al. Effects of intramuscular testosterone undecanoate on body composition and bone mineral density in female-to-male transsexuals. J Sex Med 2010; 7: 3190–98.
19. Pelusi C, Costantino A, Martelli V, et al. Effects of three different testosterone formulations in female-to-male trans-sexual persons. J Sex Med 2014; 11: 3002–11.
20. Nakamura A, Watanabe M, Sugimoto M, et al. Dose-response analysis of testosterone replacement therapy in patients with female to male gender identity disorder. Endocr J 2013; 60: 275–81
21. BhasinS, CunninghamGR, HayesFJ, MatsumotoAM, SnyderPJ, Swerdloff RS, Montori VM. Testosterone therapy in adult men with androgen deficiency syndromes: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2006 Jun; 91(6):1995-2010.
22. Gooren L. Hormone treatment of the adult trans-sexual patient. Horm Res. 2005; 64 Suppl 2:31-6.
23. Levy A. Crown A. Reid R. Endocrine intervention for trans-sexuals. Clin Endocrinol (Oxf ). 2003 Oct; 59(4):409-18.
24. Westaby D, Ogle SJ, Paradinas FJ, Randell JB, Murray-Lyon IM. Liver damage from long-term methyltestosterone. Lancet. 1977 Aug 20; 2(8034):400-1.
25. Meriggiola MC, Armillotta F , Costantino A , Altieri P , Saad F. Effects of Testosterone Undecanoate Administered Alone or in Combination with Letrozole or Dutas- teride in Female to Male Transsexuals. J Sex Med. 2008 Oct; 5 (10): 2442-53.
26. Wiepjes CM, Vlot MC, Klaver M, Nota NM.Bone Mineral Density Increases in Trans Persons After 1 Year of Hormonal Treatment: A Multicenter Prospective Observational Study. J Bone Miner Res. 2017 Jun; 32(6):1252-1260.
27. Meriggiola MC, Berra M. Safety of hormonal treatment in transgenders. Curr Opin Endocrinol Diabetes Obes. 2013 Dec; 20(6):565-9.

Authors must state that they reviewed, validated and approved the manuscript's publication.  Moreover, they must sign a model release that should be sent.  A copy may be reviewed here




Download data is not yet available.